Brought to you by:
Boston calling: Registration for VAM 2022 is open
Registration and housing for the Society for Vascular Surgery (SVS) 2022 Vascular Annual Meeting (VAM) are now open. This year’s premiere educational event for all vascular professionals is set for June 15–18 at the Hynes Convention Center in Boston. The…
Database analysis findings ‘matched precisely’ with reported reasons for venous stent recalls
A recent analysis recalled Venovo and Vici venous stents—initiated last year—characterized “significant differences” between reported device and patient issues, and subsequent interventions for the two systems, with findings ultimately matching the reasons given for the recall at the time. A…
The pandemic has been a challenge, but perhaps it imposed some equity
Years from now when we look back, will we measure time in terms of B.C. and A.C.—Before Covid and After Covid? It’s hard to imagine a time when we will we once again feel comfortable walking hospital halls without a…
Life of Achilles: Turning weakness into bursts of innovation, creativity
Themes rooted in the life of Achilles, the heroic figure from Greek mythology, and the concept of “emotional stamina” underpinned the message delivered from the presidential podium during the 2022 winter annual meeting of the Vascular and Endovascular Surgery Society…
F/BEVAR review reveals less than 20% of patients suffered intraoperative adverse event
A retrospective evaluation of 600 fenestrated or branched endovascular aneurysm repairs (F/BEVARs) for the treatment of complex aneurysms revealed that fewer than one in five patients experienced an intraoperative adverse event, according to a press release announcing study results published…
Biomarkers of heart failure show early reversal with catheter thrombolysis compared to anticoagulation alone in a secondary analysis of the SUNSET sPE trial
In a secondary analysis of the SUNSET sPE randomized control trial, lead investigator Efthymios Avgerinos, MD, of the division of vascular surgery, University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, and colleagues found differences in biomarker levels in response to treatment…
Dedicated vs. non-dedicated: Researchers place venous stenting under the spotlight at AVF 2022
Venous stenting was a hot topic on the agenda of the recent American Venous Forum (AVF) annual meeting, held this year Feb. 23–26 in Orlando, Florida. Catching the audience’s attention, researchers highlighted a head-to-head study of dedicated versus non-dedicated stents, as…
PROMISE II U.S. pivotal trial of device designed for ‘no-option’ CLTI patients completes enrollment
Enrollment has been completed in the PROMISE II pivotal trial of the LimFlow deep vein arterialization system designed to prevent amputations in so-called “no-option” chronic limb-threatening ischemia (CLTI) patients, the eponymous device maker announced today. “The PROMISE II investigators are…
Viabahn use in claudicants with long, complex SFA lesions ‘safe and effective’ through five years
Recently published research indicates that stent grafting with the Viabahn endoprosthesis (W L Gore & Associates) of long and complex superficial femoral artery (SFA) lesions in patients with claudication is a safe and effective long-term treatment option. Writing in the Journal of Vascular…
The top 10 most popular Vascular Specialist stories in February
February’s top 10 includes a highlight from the 2022 Vascular and Endovascular Surgery Society (VESS) winter annual meeting and an interview with Melissa Kirkwood, MD, and colleagues at UT Southwestern in Dallas, Texas, regarding the lightweight shield designed to reduce…